SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-133699"
 

Search: onr:"swepub:oai:DiVA.org:liu-133699" > Pegylated liposomal...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Pujade-Lauraine, EricHôpital Hôtel-Dieu, Paris, France (author)

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

  • Article/chapterEnglish2010

Publisher, publication year, extent ...

  • American Society of Clinical Oncology,2010
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-133699
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-133699URI
  • https://doi.org/10.1200/JCO.2009.25.7519DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:120965014URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • PURPOSE: This randomized, multicenter, phase III noninferiority trial was designed to test the efficacy and safety of the combination of pegylated liposomal doxorubicin (PLD) with carboplatin (CD) compared with standard carboplatin and paclitaxel (CP) in patients with platinum-sensitive relapsed/recurrent ovarian cancer (ROC).PATIENTS AND METHODS: Patients with histologically proven ovarian cancer with recurrence more than 6 months after first- or second-line platinum and taxane-based therapies were randomly assigned by stratified blocks to CD (carboplatin area under the curve [AUC] 5 plus PLD 30 mg/m(2)) every 4 weeks or CP (carboplatin AUC 5 plus paclitaxel 175 mg/m(2)) every 3 weeks for at least 6 cycles. Primary end point was progression-free survival (PFS); secondary end points were toxicity, quality of life, and overall survival.RESULTS: Overall 976 patients were recruited. With median follow-up of 22 months, PFS for the CD arm was statistically superior to the CP arm (hazard ratio, 0.821; 95% CI, 0.72 to 0.94; P = .005); median PFS was 11.3 versus 9.4 months, respectively. Although overall survival data are immature for final analysis, we report here a total of 334 deaths. Overall severe nonhematologic toxicity (36.8% v 28.4%; P < .01) leading to early discontinuation (15% v 6%; P < .001) occurred more frequently in the CP arm. More frequent grade 2 or greater alopecia (83.6% v 7%), hypersensitivity reactions (18.8% v 5.6%), and sensory neuropathy (26.9% v 4.9%) were observed in the CP arm; more hand-foot syndrome (grade 2 to 3, 12.0% v 2.2%), nausea (35.2% v 24.2%), and mucositis (grade 2-3, 13.9% v 7%) in the CD arm.CONCLUSION: To our knowledge, this trial is the largest in recurrent ovarian cancer and has demonstrated superiority in PFS and better therapeutic index of CD over standard CP.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Wagner, UwePhilipps University Marburg, Marburg, Germany (author)
  • Åvall-Lundqvist, ElisabethKarolinska Institutet(Swepub:liu)eliav51 (author)
  • Gebski, ValNHMRC Clinical Trials Centre, Sydney, NSW, Australia (author)
  • Heywood, MarkBC Cancer Agency, Vancouver, BC, Canada (author)
  • Vasey, Paul AWesley Medical Centre, Auchenflower, QLD, Australia (author)
  • Volgger, BirgitMedical University Innsbruck, Innsbruck, Austria (author)
  • Vergote, IgnaceUniversity Hospital Leuven, Leuven, Belgium (author)
  • Pignata, SandroCancer National Institute, Naples, Italy (author)
  • Ferrero, AnnamariaGynecological Oncology Institute for Cancer Research and Treatment (IRCC) of Candiolo & AO Ordine Mauriziano, Turin, Italy (author)
  • Sehouli, JalidUniversity Hospital Charité, Berlin, Germany (author)
  • Lortholary, AlainCentre Catherine De Sienne, Nantes, France (author)
  • Kristensen, GunnarNorwegian Radium Hospital, Oslo, Norway (author)
  • Jackisch, ChristianKlinikum Offenbach, Offenbach, Germany (author)
  • Joly, FlorenceCHU-Centre François Baclesse, Caen, France (author)
  • Brown, ChrisNHMRC Clinical Trials Centre, Sydney, NSW, Australia (author)
  • Le Fur, NathalieARCAGY-GINECO, Paris, France (author)
  • du Bois, AndreasDr Horst Schmidt Klinik, Wiesbaden, Germany (author)
  • Hôpital Hôtel-Dieu, Paris, FrancePhilipps University Marburg, Marburg, Germany (creator_code:org_t)

Related titles

  • In:Journal of Clinical Oncology: American Society of Clinical Oncology28:20, s. 3323-33290732-183X1527-7755

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view